1Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [ J ]. N Engl J Med,2007,356(2) :125 - 134. 被引量：1
2Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma : Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial [ J]. J Clin Oncol,2009,27 (20) :3312 -3318. 被引量：1
3Knox J, Figlin R, Stadler W, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America:Safety and efficacy [ J ]. J Clin Oncol,2007,25(18S) :5011. 被引量：1
4Escudier B, Szczylik C, Hutson T E, et al. Randomized phase H trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma [ J]. J Clin Onco1,2009,27 (8) : 1280 - 1289. 被引量：1
2Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med, 2007, 356:125-134. 被引量：1
3Wilhelm SM, Carter C,Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res, 2004, 64: 7099-7109. 被引量：1
4Awada A, Hendlisz A, Git T, et al. Safety and pharmacokinetics of BAY 43 9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer, 2005, 92: 1855-1861. 被引量：1
5Ratain MJ, Eisen T, Stadler WM, et al. Phase Ⅱ placebo controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol, 2006, 24; 2505-2512. 被引量：1
6Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alpha as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oneol, 2002, 20, 289-296. 被引量：1
7Knox JJ, Figlin RA, Stadler WM, et al. The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial in North America: Safety and efficacy. J Clin Oneol, 2007, 25(Suppl) : 241. 被引量：1
8Akaza H, Tsukamoto T, Murai M, et al. Phase Ⅱ study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. JpnJ Clin Oncol, 2007, 37: 755-762. 被引量：1
9Yang CH, Lin WC, Chuang CK, et al. Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy. Br J Dermatol, 2008, 158: 592-596. 被引量：1
10Shmidinger M, Vogl UM, Schukro C, et al. Cardiac involvement in patients with sorafenib or sunitinib treatment for metastatic renal cell carcinoma. J Clin Oncol, 2007, 25(Suppl) 293. 被引量：1
